Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Artificial intelligence in personalized prescription: A narrative review of promise, peril, and practicality.

PMID: 41966058 · 2026

JournalTherapie
Year2026
PMID41966058

Abstract

The integration of artificial intelligence (AI), particularly large language models (LLMs), into clinical prescription practices represents a transformative shift in healthcare, promising to offer enhanced therapeutic precision, reduced errors, and personalized care. However, rapid adoption is outpacing validation and governance. This narrative review critically examines the benefits, risks, and implementation challenges of AI in pharmacology, with an emphasis on prescribing use cases, highlight

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.